Topical steroidal formulations
View Patent ↗The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.
1. A method of lowering side effects in a patient undergoing treatment with a glucocorticoid comprising administering to said patient a pharmaceutical composition comprising nanosized particles of a compound of Formula I:
wherein:
R 1 , R 2 and R 7 are hydrogen;
R 3 , R 4 , R 5 and R 6 , are each individually hydrogen, or lower alkyl;
X is halogen, hydrogen or lower alkyl;
Z is hydrogen or lower alkyl; and
n is 1 or 2;
with the proviso that at least one of X and Z is not hydrogen;
suspended in a mixture comprising a lower alkyl alcohol, a surfactant, and optionally, a long chain alcohol.
2. The method according to claim 1 , wherein said glucocorticoid is selected from the group consisting of betametasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, beclomethasone, butixicort, clobetasol, flunisolide, flucatisone, momethasone, triamcinolonacetonide, triamcinolonhexacetonide GW-685698, NXC-1015, NXC-1020, NXC-1021, NS-126, P-4112, P-4114, RU-24858 and T-25.
3. The method according to claim 1 , wherein said compound of Formula I is a compound selected from the group consisting of 16α-fluoro-5-androsten-17-one, 3β-methyl-16α-fluoro-5-androsten-17-one, 16α-methyl-5-androsten-17-one, 3β-methyl-16α-methyl-5-androsten-17-one, 3β-methyl-16α-chloro-5-androsten-17-one, 16α-fluoro-5α-androstan-17-one and 16α-hydroxy-5-androsten-17-one.
4. The method according to claim 3 , wherein said compound of Formula I is 16α-fluoro-5-androsten-17-one.
5. The method according to claim 1 , wherein said pharmaceutical composition and a glucocorticoid selected from the group consisting of betametasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, beclomethasone, butixicort, clobetasol, flunisolide, flucatisone, momethasone, triamcinolonacetonide, triamcinolonhexacetonide GW-685698, NXC-1015, NXC-1020, NXC-1021, NS-126, P-4112, P-4114, RU-24858 and T-25, are administered at the same time.
6. The method according to claim 1 , wherein said side-effect is selected from the group consisting of: adrenocortical suppression, osteoporosis, bone necrosis, steroid-induced cataracts, steroid-induced obesity, corticosteroid-induced psychosis, gastrointestinal hemorrhage, thymic atrophy, splenic atrophy skin atrophy, hyperglycemia or increased requirement for insulin or oral anti-diabetic drugs, cortisol-induced myopathy, and benign intracranial hypertension.
7. The method according to claim 1 , wherein said patient is receiving anti-cancer treatment.
8. The method according to claim 1 , wherein said pharmaceutical composition is administered transdermally.
9. The method according to claim 1 , wherein said long chain alcohol corresponds to the formula CH 3 (CH 2 ) n —OH, wherein n is an integer in the range of 9-24.
10. The method according to claim 9 , wherein said long chain alcohol is selected from the group consisting of decyl alcohol, cetyl alcohol, stearyl alcohol, lauryl alcohol, myristyl alcohol, oleyl alcohol and mixtures thereof.
11. The method according to claim 1 , wherein the suspension further comprises water.
12. The method according to claim 1 , wherein said surfactant is a polysorbate or a polyethyleneglycol substituted fatty acid.
13. The method according to claim 12 , wherein said polysorbate is selected from the group consisting of polyoxyethylene-20-sorbitan monooleate (Tween 80), polyoxyethylene-20-sorbitan monostearate (Tween 60), polyoxyethylene-20-sorbitan monopalmitate (Tween 40), polyoxyethylene-20-sorbitan monolaurate (Tween 20), and mixtures thereof.
14. The method according to claim 13 , wherein the suspension comprises a lower alkyl alcohol in the range of from about 30 to about 90% (v/v), polyoxyethylene-20-sorbitan monooleate (Tween 80) in the range of from about 0.01% to about 3.5%, and water in the range of from about 0% to about 60%.
15. The method according to claim 1 , wherein said pharmaceutical composition is administered in the form of a gel further comprising water, a thickening agent, and optionally a base.
16. The method according to claim 15 , wherein said compound of Formula I is 16α-fluoro-5-androsten-17-one.
17. The method according to claim 15 , wherein said polysorbate is selected from the group consisting of polyoxyethylene-20-sorbitan monooleate (Tween 80), polyoxyethylene-20-sorbitan monostearate (Tween 60), polyoxyethylene-20-sorbitan monopalmitate (Tween 40), polyoxyethylene-20-sorbitan monolaurate (Tween 20), and mixtures thereof.
18. The method according to claim 1 , wherein said lower alkyl alcohol is selected from the group consisting of ethanol, methanol, butanol, pentanol, isopropanol and n-propanol.
19. The method according to claim 15 , wherein said base is selected from the group consisting of triethanolamine, diethanolamine and triethylamine.
20. The method according to claim 15 , wherein said surfactant is a polysorbate or a polyethyleneglycol substituted fatty acid.
21. The method according to claim 20 , wherein the surfactant is a polysorbate.
22. The method according to claim 15 , wherein said lower alkyl alcohol is selected from the group consisting of ethanol, methanol, butanol, pentanol, isopropanol and n-propanol.